Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective, Cohort Study on the Treatment of Metastatic Hormone-sensitive Prostate Cancer Patients Who Have Progressed After Pre-treatment With Rezvilutamide Combined With Abiraterone

NCT06134271 is registered in ClinicalTrials.gov with Jianbin Bi as lead sponsor.

NCT NCT06134271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06134271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective, Cohort Study on the Treatment of Metastatic Hormone-sensitive Prostate Cancer Patients Who Have Progressed After Pre-treatment With Rezvilutamide Combined With Abiraterone
Lead sponsor
Jianbin Bi
Phase
Phase 2
Overall status
Unknown status
Start date
November 15, 2023
Completion date
April 30, 2026
Enrollment
160 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer